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Abstract: Background: In recent years, higher than the recommended rate of oxytocin use has
been observed among low-risk women. This study examines the relationship between oxytocin
administration and birth outcomes in women and neonates. Methods: A retrospective analysis
of birth and neonatal outcomes for women who received oxytocin versus those who did not. The
sample included 322 women with a low-risk pregnancy. Results: Oxytocin administration was
associated with cesarean section (aOR 4.81, 95% CI: 1.80–12.81), instrumental birth (aOR 3.34, 95%
CI: 1.45–7.67), episiotomy (aOR 3.79, 95% CI: 2.20–6.52) and length of the second stage (aOR 00:18,
95% CI: 00:04–00:31). In neonatal outcomes, oxytocin in labor was associated with umbilical artery
pH ≤ 7.20 (OR 3.29, 95% CI: 1.33–8.14). Admission to neonatal intensive care unit (OR 0.56, 95% CI:
0.22–1.42), neonatal resuscitation (OR 1.04, 95% CI: 0.22–1.42), and Apgar score <7 (OR 0.48, 95% CI:
0.17–1.33) were not associated with oxytocin administration during labor. Conclusions: Oxytocin
administration during labor for low-risk women may lead to worse birth outcomes with an increased
risk of instrumental birth and cesarean, episiotomy and the use of epidural analgesia for pain relief.
Neonatal results may be also worse with an increased proportion of neonates displaying an umbilical
arterial pH ≤ 7.20.
Keywords: term birth; obstetric labor; oxytocin; low-risk pregnancy; birth outcome; neonatal outcome
1. Introduction
Oxytocin is an endogenous hormone, produced in the hypothalamus and secreted
by a feedback mechanism by the pituitary gland [1]. Its role during labor and birth is
to generate rhythmic contractions of the uterine smooth muscle to ensure progressive
dilatation and eventually the birth [2].
Synthetic oxytocin can be administered to commence or increase uterine activity
during labor. Administering exogenous oxytocin while the endogenous form is being
released can overwhelm the feedback mechanism leading to an ineffective regulation of
uterine activity with potentially disastrous consequences for the mother and fetus [3].
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Oxytocin is considered a high-risk drug by the Institute for Safe Medication Practices.
High-risk drugs are those that, when used inappropriately, have the highest potential to
cause severe harm to patients [4].
The Normal Birth Care Strategy published in 2008 by the Spanish Ministry of Health
establishes standards for intrapartum care in Spain for women with a low-risk pregnancy
and labor [5]. It recommends that no more than 10% of women in this group should
undergo induction of labor (IOL) or augmentation of labor (AOL).
There is a paucity of data on the use of oxytocin among low-risk women and the
available evidence shows wide variations in its use. In Spain, a study to evaluate the
implementation of the Normal Birth Care Strategy shows a rate of 19.4% IOL and 53.3%
AOL, amply surpassing its recommendations [6]. A Swedish study observed a 33% oxytocin
use [7], while a French study showed a rate above 60% [8] and in the United States, Iobst
et al. reported that 44% of low-risk nulliparous women had oxytocin administered during
labor [9].
One of the explanations as to why rates of oxytocin use vary so widely may lie in the
fact that specifying the reason for administration of oxytocin in the woman’s records is not
globally or homogeneously recorded (i.e., using the same codes or diagnostic criteria for
example to diagnose slow labor). The reason for oxytocin administration should be identi-
fied in each case, and close monitoring should be implemented throughout the process,
to observe for uterine response in each woman. Based on the reason for administration,
the lowest possible dose must be used, and it should not be increased earlier than every
30 min. This will allow us to assess whether the current dose is sufficient or whether further
oxytocin is needed [10].
International scientific bodies have established the indications for oxytocin adminis-
tration during labor [11–13]. However, several studies suggest excessive and unnecessary
use of oxytocin intrapartum: rather than treating labor dystocia, oxytocin is being used to
prevent it with the potential increase in unnecessary complications [14,15].
Oxytocin administration during labor is associated with negative obstetric outcomes,
such as an increase in the rate of the cesarean section following IOL [16], an increase in
instrumental birth and episiotomy following AOL [14,15,17], and an increased risk of
postpartum hemorrhage (PPH) [18]. Oxytocin administration is also associated with poorer
neonatal outcomes such as an increased risk of admission to the neonatal intensive care
unit (NICU) [19,20], neonatal acidemia [21,22], lower Apgar scores, and greater need for
neonatal resuscitation [7,15,23].
Furthermore, a Swedish study by Ekelin et al. found that the majority of midwives
they interviewed thought that the use of oxytocin to accelerate labor was being used
excessively and unnecessarily in most cases [24].
This backdrop seems to indicate that the use of oxytocin may be guided by a desire
to prevent specific undesirable maternal and neonatal outcomes, without paying due
attention to the added, unintended negative consequences that using oxytocin can bring
and which are well described within the scientific literature [25]. It is therefore imperative
that clear guidelines are developed for the appropriate use of oxytocin for IOL and AOL.
The idea for our study stems from the higher than recommended rate of oxytocin use
among low-risk women within our setting.
Before we can put in place measures to ensure more judicious use of oxytocin in labor,
we must first gain a better understanding of what are the factors and circumstances of
its use, including the reasons and situations in which it is being employed. We should
also compare our results with similar studies, as well as assess whether we comply with
international recommendations. Finally, we must evaluate the impact that oxytocin use
can have on women and neonates.
With this in mind, the objective of our study is to analyze the use of oxytocin in low-
risk women in our setting and its impact on maternal and neonatal outcomes. The results
of this study will help inform strategies and measures to provide a more physiological
approach to labor care.
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2. Materials and Methods
This is a retrospective observational study with prospectively collected data.
The study population is comprised of women who gave birth at the General Hospital
of Granollers between 1 October 2016 and 1 April 2017. The birth rate at the hospital is
around 1500 births per year.
Consecutive enrolment was carried out for those participants meeting inclusion criteria
until the end of the recruitment period. Data were entered in a pre-designed data collection
sheet and they were then inputted into an electronic database.
Inclusion criteria: pregnant women between 18 and 40 years old, with a single, cephalic
presentation, low-risk pregnancy at the time of admission in labor according to prenatal
care protocol in Catalonia [26], which starts between 37 + 0 and 41 + 6 weeks of gestation.
Exclusion criteria: pregnant women 17 years or younger or 41 years or older; multiple
pregnancies; women who were admitted for an elective cesarean section; any fetal presen-
tation other than cephalic; women not classified as low-risk at the time of admission in
delivery suite according to prenatal care protocol in Catalonia and a start of labor before
37 + 0 or after 41 + 6.
Prenatal care protocol in Catalonia defines a woman with a low-risk pregnancy as a
pregnant woman who has a physical characteristic, a physiological history or a pathology
that does not require resources or specialized care. The criteria that define the gestational
risk classification are well specified in the protocol and the risk classification is carried out
continuously by the midwife during the antenatal follow-ups (Figure 1).
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In our country, delivery care for women with low-risk pregnancy is mostly performed
by midwives. Women in Catalonia cannot choose an elective IOL on their own, as IOL is
indicated by an obstetrician under a woman’s informed consent.
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Including in the study low-risk women who had an IOL may seem contradictory, as
induction itself renders the pregnancy and labor high-risk. However, healthy women who
have an elective IOL for no medical reason [27] represent a considerable proportion of
laboring women, and it is thought to be on the increase [28]. It is estimated that this group
of women could make up around 20% of all IOL [29,30]. A separate analysis for this group
of women was carried out to identify the added risks these women were subjected to.
Participants’ socio-demographic data were collected, as well as data about maternal,
birth and neonatal outcomes.
At the Hospital General de Granollers, an obstetrician must be consulted before
initiating oxytocin infusion. The prescribed dose of oxytocin infusion is 5 IU in 500 mL
physiological saline with an initial dose of 2 mU/min, the dose is increased by 2 mU/min
in AOL and in IOL is doubled until it reaches 8 mU/min. Then it is increased by 2 mU/min
until five contractions in 10 min are reached or until the maximum dose of 20 mU/min.
The main variable under study is the administration of oxytocin during the first and
second stages of labor, as the administration of 5 IU of oxytocin during the third stage of
labor for placental delivery is common practice in the study setting.
Birth outcome measures included instrumental birth, cesarean section, episiotomy
and PPH (blood loss >500 mL).
Neonatal outcome measures comprised an Apgar of <7 at 1 and 5 min of life, the need
for neonatal resuscitation at birth, admission to NICU and arterial umbilical pH ≤ 7.20.
We conducted a comparative analysis of birth and neonatal results between women
who had oxytocin administered in labor and those who did not. Women who received
oxytocin did so intending to induce or accelerate labor. We also assessed whether the
neonatal and birth results were associated with the reason for oxytocin administration. All
women in this study received intravenous oxytocin when augmented or induced.
Dependent variables were the mode of delivery, presented as cesarean section, instru-
mental vaginal birth and spontaneous birth, postpartum hemorrhage >500 mL, episiotomy,
length of first and second stage labor, neonatal resuscitation, umbilical artery Ph ≤ 7.20,
transfer to the neonatal intensive care unit and Apgar score < 7 at one and five minutes.
Independent variables were oxytocin administration and indication to oxytocin adminis-
tration (IOL versus AOL)
For quantitative variables following a normal distribution, we used the mean and
standard deviation. To analyze non-parametric variables, we used the median (1–3 quartile
range). Quantitative variables were compared using Student’s t-test. Non-parametric tests
were used for the variables of first and second stage lengths as they did not follow a normal
distribution; this analysis was only conducted for vaginal births as no data was available
for cesarean births.
The Odds Ratio (OR) was calculated with a CI of 95%. The variables selected to
conduct the Odds Ratio analysis were identified based on their possible impact on birth
and neonatal outcomes as per available scientific evidence, for example, the effect of an
epidural on cesarean section [31]. Adjusting variables were parity, peridural analgesia,
birth weight, gestational age, vaginal birth and oxytocin indication. p < 0.05 was considered
statistically significant. The first stage length was estimated from the onset of the active
phase or admission to the labor ward if they had already reached this phase. In the cesarean
section, if the first and/or second stage of labor was not completed, these lengths were not
analyzed. Finally, a univariate logistic regression was conducted to establish associations
between the variables; to adjust for confounding factors, multivariate logistic regression
was carried out.
When adjusting neonatal results per type of birth, cesarean sections were excluded
from the analysis to avoid bias: for those cesareans performed for fetal compromise, it
would not have been possible to determine if administration of oxytocin was the cause of
such compromise.
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We did not conduct a multivariate analysis for those variables with few cases (Apgar
score <7 at 5 min, 3 cases; 3rd and 4th-degree perineal damage, 4 cases; umbilical artery
pH < 7.10, 6 cases; cesarean section in multiparous women without oxytocin, 0 cases; PPH
in primiparous women without oxytocin, 0 cases).
Ethical Statement: The project was approved by the Ethics Committee (Clinical Re-
search Ethics Committee of Hospital de Granollers) on 6 June 2016 (approval number:
20162012) and was also approved by the board of directors of the hospital as it is customary
in our setting. The ethics committee of the hospital required consent from the women
and written consent was obtained. Further information and documentation are available
on request.
3. Results
Of a total of 755 births during the study period, 329 women met the inclusion criteria,
6 women refused to participate in the study, and 1 woman was excluded from study owing
to incomplete data. The final study population was 322 women (Figure 2).
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n % n % Total p-Value
Maternal age in years
(mean/sd) 31/5.14 30/5.4 322 0.27
Length of the first stage of
labor * (median/IQR) 345/235 240/236 301 0.01
Length of the second stage of
labor* (median/IQR) 40/66 24/43 301 <0.01
Nationality
Spanish 152 65.8% 44 48.9% 197
European 13 5.6% 3 3.3% 16
South-Central American 17 7.4% 9 10.0% 26
African 45 19.5% 31 34.4% 76
Asian 4 1.7% 3 3.3% 7 0.03
Educational level
Primary studies 74 31.9% 39 43.3% 113
Secondary studies 84 36.2% 21 23.3% 105
University studies 66 28.4% 25 27.8% 91
Unknown 8 3.4% 5 5.6% 13 0.09
Gestational age
37 weeks 12 5.2% 13 14.4% 25
38 weeks 30 12.9% 11 12.2% 41
39 weeks 59 25.4% 28 31.1% 87
40 weeks 71 30.6% 27 30.0% 98
41 weeks 60 25.9% 11 12.2% 71 0.01
Parity
Nulliparous women 140 60.3% 31 34.4% 171
Multiparous women 92 39.7% 59 65.6% 151 <0.01
Birthweight **
<3000 43 18.5% 17 18.9% 60
3000–3500 106 45.7% 50 55.6% 156
3501–4000 68 29.3% 20 22.2% 88
>4000 15 6.5% 3 3.3% 18 0.30
* Time expressed in minutes. ** Weight expressed in grams. Sd: Standard deviation; IQR: Interquartile range.
Oxytocin was administered in a greater proportion to women with the following
characteristics: Spanish nationality (65.8%), secondary studies (36.2%), 40 weeks gestational
age at the time of birth (30.6%), nulliparous women (60.3%) and those with neonates
weighing between 3000 g and 3500 g (45.7%)
Women who were administered oxytocin had longer first and second stages of labor
(46 min; p = 0.01, and 18 min; p < 0.01 respectively).
The most prevalent type of birth in this group of women was spontaneous vaginal
(66.7%), followed by an instrumental (22%) and finally a cesarean section (8.2%).
We found the greatest proportion of women who had been administered oxytocin
among those women who had a cesarean section (90.5%), followed by those who had an
instrumental birth (87.9%). These differences were statistically significant (p < 0.01).
Overall, women who had oxytocin administered during labor sustained more inter-
ventions such as epidural analgesia (EA) (97.8% of women; p < 0.01), artificial rupture of
membranes (ARM) (57.3% of women, although this did not reach statistical significance;
p = 4.08) and episiotomy (58.7% of women; p < 0.01).
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With regard to PPH, this occurred in a greater proportion among those who received
oxytocin (5.6% versus 1.1% among those who did not receive it). However, these values
reached no statistical significance (p = 0.08).
On the other hand, there was a greater percentage of neonates whose mothers received
oxytocin during labor who scored <7 in the Apgar test at 1 min of life (56.3%; p = 0.15). A
score <7 at 5 min was more prevalent among those neonates whose mothers did not receive
oxytocin (66.7%; p = 0.13), although only 3 cases were reported.
Mothers whose neonates required resuscitation were more likely to have been admin-
istered oxytocin (72.7%; p = 0.96). Neonates admitted to NICU were in greater proportion
born to mothers who had been administered oxytocin too (60%; p = 0.22). The most sig-
nificant difference was between the administration of oxytocin and a pH ≤ 7.20. This
was more prevalent among those neonates whose mothers had received oxytocin in labor
(87.8%; p = 0.01).
We conducted a logistic regression (Table 2) to understand the impact that oxytocin
administration had on birth outcomes.
Table 2. Crude and adjusted OR for birth outcomes with oxytocin as a predictor.
Crude OR Adjusted OR
OR
95% CI p-Value Adj OR 95% CI p-Value
Lower Upper Lower Upper
Cesarean section 3.93 0.90 17.21 0.07 4.81 * 1.80 12.82 <0.01
Instrumental birth 3.64 1.58 8.39 <0.01 3.34 ** 1.45 7.67 <0.01
Episiotomy 6.13 3.26 11.53 <0.01 3.79 † 2.20 6.52 <0.01
Postpartum hemorrhage 5.28 0.68 4.99 0.11 1.55 ‡ 0.49 4.91 0.46
Length of first stage labor (hh:mm) 0:46 0:00 1:32 0.05 0:46 § −0:02 1:35 0.06
Length of second stage labor (hh:mm) 0:18 0:04 0:31 0.01 0:18 § 0:04 0:31 0.01
* Analyses were adjusted for parity, epidural analgesia, birth weight and gestational age. ** Analyses were adjusted for parity, epidural
analgesia and birth weight. † Analyses were adjusted for parity, epidural analgesia and vaginal birth. ‡ Analyses were adjusted for parity,
epidural analgesia and gestational age. § Analyses were adjusted for parity and epidural analgesia. CI: Confidence Interval; OR: Odds
Ratio; aOR: adjusted Odds Ratio.
This showed a non-significant increase in cesarean sections. However, when we
adjusted for confounders, it became significant (aOR 4.81; CI 95% 1.80–12.82; p < 0.01).
When we adjusted the results of other birth variables for confounding, we did not
observe differences between crude and adjusted OR. There was an increased probability of
labor resulting in an instrumental birth (aOR 3.34; CI 95% 1.45–7.67; p < 0.01). Likewise,
episiotomy was more readily performed in the presence of oxytocin (aOR 3.79; CI 95%
2.20–6.52; p < 0.01). PPH had a positive association among those women who received
oxytocin; however, this did not reach statistical significance (aOR 1.55; CI 95% 0.49–4.91;
p = 0.46).
Equally, the length of the first stage of labor was increased in the presence of oxytocin
(by 46 min), but this was not statistically significant (p = 0.05). In contrast, the length of
the second stage of labor increased by 18 min and this did reach statistical significance
(p < 0.01).
Following adjustment for parity (Table 3), we observed that nulliparous women
who received oxytocin had a positive association with cesarean section (OR 1.08; CI 95%
0.88–1.32; p = 0.54) and instrumental birth (OR 1.14; CI 95% 1.00–1.30; p = 0.09) although
neither reached statistical significance. We could not assess the risk of cesarean section
among multiparous women due to a lack of cases in the group who did not receive oxytocin.
The use of EA in the presence of oxytocin was influenced by parity: multiparous
women used it more frequently than nulliparous women (OR 9.63; CI 95% 3.24–28.61;
p < 0.01 versus OR 4.29; CI 95% 1.24–14.83; p < 0.01).
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With regard to the incidence of episiotomy in the presence of oxytocin, primiparous
women were at higher risk than multiparous women (OR 1.75; CI 95% 1.06–2.86; p < 0.01
versus OR 1.66; CI 95% 1.18–2.33; p < 0.01).
We could not assess the risk of PPH among primiparous women due to a lack of cases
in the group who not received oxytocin and for multiparous women, we saw an increased
risk, albeit not a statistically significant one (OR 1.39; CI 95% 0.95–2.03; p = 0.25).
The length of the first and second stages of labor did not show statistical significance
between nulliparous and multiparous women who received oxytocin in labor.
We also adjusted the OR by reason for administration (IOL and AOL) (Table 3). When
oxytocin was administered for IOL, the risk of cesarean section increased significantly
(OR 2.20; CI 95% 1.64–2.96; p < 0.01). The risk of instrumental birth increased when oxytocin
was administered for IOL or AOL (OR 1.69; CI 95% 1.17–2.44; p = 0.02 versus OR 1.39; CI
95% 1.18–1.65; p < 0.01).
Administration of oxytocin for either IOL or AOL had a positive association with the
use of EA (IOL: OR 4.54; CI 95% 1.36–15.11; p < 0.01) (AOL: OR 32.26; CI 95% 1.67–135.68;
p < 0.01). Furthermore, the positive association was also shown with episiotomy when
oxytocin was administered for IOL or AOL (OR 2.82; CI 95% 1.55–5.14; p < 0.01 versus OR
2.12; CI 95% 1.53–2.95; p < 0.01). Both IOL and AOL increased the risk of PPH although
the values only showed statistically significant results in IOL (OR 2.01; CI 95% 1.34–3.01;
p = 0.04).
Women who had oxytocin for AOL had the first stage of labor 56 min longer than
those women who did not receive oxytocin (p = 0.03) and the second stage of labor was
23 min longer (p <0.01).
We also adjusted for use of EA and the results indicate that the use of this in women
who received oxytocin during labor did not increase the risk of cesarean (p = 0.05) or PPH
(p = 0.08). However, it did show positive association in instrumental births (OR 3.34; CI95%
1.45–7.67; p < 0.01) and episiotomy (OR 3.79; CI95% 2.20–6.52; p < 0.01).
EA also increases the length of the first stage of labor, but not in a statistically signifi-
cant manner (p = 0.56). On the other hand, EA increases the length of the second stage of
labor by 44 min (p < 0.01), but only among those women who did not receive oxytocin.
The logistic regression for neonatal results showed that when oxytocin was adminis-
tered, the probability of obtaining a pH ≤ 7.20 from the umbilical artery was greater than
when oxytocin was not used (OR 3.29; CI 95% 1.33–8.14; p < 0.01). The probability to obtain
a score of <7 in the Apgar test at one minute of life (OR 0.48; CI 95% 0.17–1.33; p = 0.15) did
not increase significantly when oxytocin was administered. This was the same for neonatal
resuscitation (OR 1.04; CI 95% 0.22–1.42; p = 0.96) and the need for admission to NICU (OR
0.56; CI 95% 0.22–1.42; p = 0.22).
We adjusted OR by type of vaginal birth with oxytocin administration during labor as
a predictor (Table 4).
We observed that instrumental birth had a negative association with Apgar test <7 at
one minute of life (aOR 0.05; CI 95% 0.01–0.43; p < 0.01), and also spontaneous birth showed
a negative association with neonate admission to NICU (aOR 0.24; CI 95% 0.06–0.97;
p = 0.05). However, low umbilical artery Ph (≤7.20) and the need for neonatal resuscitation
did not reach statistical significance.
Finally, we calculated the OR for the reason of oxytocin administration (Table 4).
IOL and AOL had a positive association for umbilical artery Ph ≤7.20 (aOR 3.71; CI
95% 1.32–10.46; p = 0.01 and aOR 3.12; CI 95% 1.23–7.95; p = 0.02 respectively). IOL
showed a positive association with neonatal resuscitation and NICU admission, but without
statistical significance.
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Table 3. Adjusted OR for birth outcomes with oxytocin as a predictor by parity and oxytocin indication.
Adjusted OR by Parity Adjusted OR by Oxytocin Indication
Nulliparous Multiparous IOL AOL
aOR
95% CI p-Value aOR
95% CI p-Value aOR
95% CI p-Value aOR
95% CI p-Value
Lower Upper Lower Upper Lower Upper Lower Upper
Cesarean section 1.08 0.88 1.32 0.54 - - - - 2.20 1.64 2.96 <0.01 1.21 0.85 1.74 0.40
Instrumental birth 1.14 1.00 1.30 0.09 1.30 0.89 1.89 0.29 1.69 1.17 2.44 0.02 1.39 1.18 1.65 <0.01
Epidural analgesia 4.27 1.24 14.83 <0.01 9.63 3.24 28.61 <0.01 4.54 1.36 15.11 0.01 13.84 3.55 53.92 <0.01
Episiotomy 1.75 1.06 2.86 <0.01 1.66 1.18 2.33 <0.01 2.82 1.55 5.14 <0.01 2.12 1.53 2.95 <0.01
Postpartum hemorrhage - - - - 1.39 0.95 2.03 0.25 2.01 1.34 3.01 0.04 1.40 1.09 1.79 0.12
Length of first stage labor (hh:mm) −0:08 −1:20 1:03 0.81 0:37 −0:23 1:38 0.23 0:18 −0:45 1:23 0.57 0:56 0:06 1:46 0.03
Length of second stage labor (hh:mm) 0:14 −0:10 0:39 0.26 0:01 −0:07 0:10 0.72 0:07 −0:08 0:24 0.33 0:23 0:10 0:36 <0.01
IOL: Induction of labor; AOL: Augmentation of labor; CI: Confidence Interval; aOR: Adjusted Odds Ratio.
Table 4. Crude and adjusted OR for neonatal outcomes with oxytocin as a predictor by type of vaginal birth and oxytocin indication.
Adjusted OR by Type of Vaginal Birth Adjusted OR by Oxytocin Indication
Instrumental Birth Spontaneous Birth IOL AOL
aOR
95% CI p-Value aOR
95% CI p-Value aOR
95% CI p-Value aOR
95% CI p-Value
Lower Upper Lower Upper Lower Upper Lower Upper
1 min Apgar test < 7 0.05 0.01 0.43 0.01 1.52 0.30 7.70 0.61 0.55 0.14 2.20 0.40 0.45 0.15 1.38 0.16
Neonatal resuscitation 0.51 0.05 5.36 0.58 0.75 0.12 4.55 0.75 1.34 0.26 6.85 0.73 0.91 0.21 3.91 0.90
Admission to NICU 0.65 0.07 6.57 0.72 0.24 0.06 0.97 0.05 1.18 0.41 3.42 0.77 0.32 0.10 1.02 0.05
Umbilical artery Ph ≤ 7.20 2.14 0.22 20.94 0.51 2.72 0.98 7.55 0.05 3.71 1.32 10.46 0.01 3.12 1.23 7.95 0.02
IOL: Induction of labor; AOL: Augmentation of labor; CI: Confidence Interval; aOR: Adjusted Odds Ratio.
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4. Discussion
Our study population comprised low-risk women, yet the rates of oxytocin use are
higher than those reported by other studies [8,14]. Furthermore, they are higher than those
recommended by the Normal Birth Care Strategy [5] which recommends that AOL for
women who start labor spontaneously should stand between 5–10%. In stark contrast, our
results show 50.9% of women were augmented with oxytocin during labor. With regard to
IOL, the strategy considers that less than 10% of labors should be induced, while our rates
show an incidence of 21.1%, similar to other studies which have quantified elective IOL for
low-risk women [29,30].
Women in our study who received oxytocin in labor were more likely to require EA
than those who did not receive it. These results are similar to those reported by other
studies which showed a correlation between the use of oxytocin in labor (either for IOL or
AOL) and the use of EA [14,19,32–34].
However, the rates reported by those studies were much lower than the ones we
obtained in our study where 85% of all women used EA, and this was even higher among
those who received oxytocin in labor: 97.8%. Current recommendations suggest EA should
stand between 30–80% of women [5].
The available literature offers conflicting evidence on the association between EA and
poor obstetric outcomes [34,35]. When parity was included in the regression analysis for
the group of women who received oxytocin in our study, the adjusted OR showed that
the use of EA was higher among multiparous women. Both nulliparous and multiparous
women had a high EA use.
Despite this strong link between the administration of oxytocin and EA use in our
study, we are unable to discern whether high EA use is the consequence of oxytocin
administration in labor (because it is a more painful process) or because women who are
administered oxytocin are more fearful of painful labor and request EA more readily.
ARM was conducted more frequently in the group of women who received oxytocin,
but this did not reach statistical significance. The overall rate of ARM in our study was
55.9%, whereas ARM among women who received oxytocin was 1.4% higher. This may
point to a routine overuse of an unnecessary intervention for low-risk women, which con-
travenes national and international recommendations [5,11,36–38]. Furthermore, routine
use of this intervention has proven to be ineffective in preventing labor dystocia [12].
The duration of the first and second stages of labor in women receiving oxytocin
was longer. This represents a puzzling paradox: attempting to reduce the length of labor
through the administration of oxytocin may lead to longer labors. According to a systematic
review comparing low doses versus high doses of oxytocin, a shortening of the first stage
of labor was only achieved when oxytocin was administered in high doses [39]. Based
on this premise, we analyzed the type of oxytocin doses administered in our center and
we saw that they were low according to Kenyon et al.’s classification (low-dose regimens:
defined as starting dose of 4 mU per minute and an increment of less than 4 mU per minute
with an increased interval between 15 and 40 min).
While some studies have shown that IOL is associated with longer first and second
stages of labor [40], our results are contrasting and show a reduction of these times, however,
these were not statistically significant. On the other hand, we observed an increase in the
length of labor in the AOL group. When we analyzed the length of the first and second
stages of labor and adjusted the OR we saw that EA is not a confounding factor, while
parity is.
Regarding cesarean section, we observed that oxytocin was not a risk factor, but
when we adjusted the OR by reason for its administration, we saw that when used to
induce labor, it carried a significantly higher risk for cesarean. The associated risk between
IOL and cesarean section has already been reported in other studies [16,19]. Conversely,
these findings disagree with the latest Cochrane reviews and others [41,42] who compare
IOL with expectant management of labor. Studies whose results are consistent with ours
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compare IOL with spontaneous onset of labor. Therefore, the discrepancy between studies
may be due to the methodology used.
The association has also been found even when controlling for pregnancy risk [20]
and other different interventions associated with oxytocin administration [9].
When EA was administered to women receiving oxytocin, the risk of cesarean was
not increased. These findings are in line with a recent systematic review [43] which found
no relationship between EA and cesarean section.
Some studies have found a relationship between instrumental births and oxytocin
administration when a misdiagnosis of labor dystocia had been made [14,15]. The level
of risk for instrumental birth when oxytocin is used to augment the labor in our study is
similar to those found by a Norwegian study [17] and with similar rates of AOL. However,
we obtained higher risk levels than those reported by other studies [14,15]. This may be
explained by the higher incidence of AOL among our study population and by being in a
university hospital where obstetrics specialists are trained.
The high episiotomy rate seen among those women who received oxytocin can be
explained by the greater incidence of instrumental births among them and it is similar
to those findings by another study that analyzed adverse birth outcomes in low-risk
nulliparous women under oxytocin administration [14].
In terms of PPH, there were no statistically significant differences between women
who received oxytocin in labor and those who did not. After adjusting for the indication
to oxytocin administration, results showed a positive association between IOL and PPH;
according to Rousseau et al., this association of risk of PPH and oxytocin administration
may be related to the dose administered [18], which leads us to think our results are because
high doses of oxytocin are always more associated with IOLs.
With regard to neonatal complications, our results show that oxytocin administration
is not a risk factor for admission to NICU. However, when we conducted a subanalysis
for the reason of administration we found that when oxytocin was administered to induce
labor, there was no statistically significant increased risk association of admission to NICU.
These findings coincide with others [19,44].
The risk of obtaining a pH ≤ 7.20 in the umbilical artery is higher when oxytocin is
administered during labor. These results are similar to those found by Hidalgo-Lopezosa
et al. [45]. Jonsson et al., in 2008, associated neonatal acidemia with uterine hyperstimula-
tion and oxytocin administration [21] and Bakker et al., in 2007, also found an association
between excessive uterine activity and low pH values [22]; our study did not collect data
on uterine activity, therefore this association was been demonstrated.
With regard to the other neonatal outcomes we measured in our study (Apgar test
at 1 and 5 min of life, the need for neonatal resuscitation and admission to NICU), we
did not find any association with the use of oxytocin. However, other studies using
different methodologies have found a relationship between oxytocin administration during
labor and lower Apgar results, greater need for neonatal resuscitation and admission to
NICU [7,15,23,46].
Several studies have demonstrated that identifying the optimal time for commencing
oxytocin, captured in guidelines that also stipulate the appropriate dose to employ, can
reduce the risk of neonatal complications such as low Apgar scores and admission to NICU,
as well as maternal complications, including cesarean section [17,46,47].
4.1. Strengths and limitations
Our study offers some tools to understand that oxytocin administration during low-
risk labor may not be an innocuous intervention and can result in a series of complications
for both the mother and neonate.
Following the analysis of our results, we identify the need to continue researching
the use of different unnecessary labor interventions which can be considered endemic in
our practice area. This would allow us to develop strategies to provide maternity care that
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is more aligned with the promotion of labor physiology and more in synchronicity with
women’s wishes [48,49].
The main limitation of our study lies in its observational methodology, given the
need to rely on previously recorded variables. This limits our ability to establish causal
relationships, such as the use of EA and its association with oxytocin administration. We
were not able to establish whether EA was used more in the presence of oxytocin because
the latter makes labor more painful, or whether EA led to a higher need in oxytocin use
because it interfered with effective uterine contractions.
There is a paucity of data examining the complications arising as a result of adminis-
tering oxytocin to low-risk women, and it was, therefore, difficult to compare our results
with other studies.
The reason why oxytocin is employed both for IOL and AOL is not routinely recorded
in obstetric records in Spain. Therefore, we were unable to ascertain whether the use of
oxytocin was justified or not.
4.2. Implications for the Practice and Research
Given these results, it would seem reasonable to suggest that optimizing safety and
standardization of oxytocin administration criteria is required as a matter of priority [50,51].
In particular, evidence-based guidelines on the appropriate oxytocin use and its dosage
would contribute to improve outcomes and reduce unwanted ones. Outcome indicators
that allow for ongoing assessment of adherence, effectiveness and review based on the
latest research would also be beneficial [52].
However, our results also show excessive and possibly inappropriate use of other labor
interventions in low-risk women, with rates of episiotomies, EA and ARM greater than
those recommended in the national and international literature [11–13]. These interventions
during normal childbirth have been steadily increasing over the last few decades in the
developed world in the absence of evidence of their benefit. The contrary is happening:
the scientific evidence demonstrates that this over intervention is causing harm to mothers,
babies and families [25].
To optimize maternity care provision for low-risk women, the medicalization and
hierarchical organization of childbirth care provision must be tackled as these factors
obstruct the effective use of midwives’ skills in providing care for them, hinders care
provision based on the holistic needs of women and prevents them from voicing their
opinions and preferences [53].
However, an improvement in the use of oxytocin administration and other obstetric
interventions should not happen as an isolated practice change but needs to be embedded
within a culture of approaching labor care from a more physiological perspective, where
respect for the process and a belief in the ability of women’s bodies to successfully give
birth with minimal intervention is intrinsic to the philosophy of care of every maternity unit.
Furthermore, a discourse around respectful maternity care which is gathering momentum
around the world [54] needs to be had across Spanish birth settings.
5. Conclusions
The results of this study show that oxytocin administration for low-risk women may
not be an innocuous intervention. Its use must be adequately justified through consensual
guidelines based on the latest national and international research and recommendations.
It appears that the use of oxytocin for low-risk women surpasses the levels recom-
mended by the National Strategy [5]. The extent of complications arising as a result of the
use of oxytocin appears to be lower than in other studies, possibly because of the lower
dosages employed in our setting. Nonetheless, efforts need to be focused on ensuring more
judicious use of the drug.
Oxytocin is thought to be used to reduce detrimental labor outcomes, but our results,
which confirm other studies’ findings, show an association between oxytocin administra-
tion and a higher number of instrumental births, cesarean sections, use of episiotomy and
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EA. Neonatal outcomes are also adversely affected by the use of oxytocin, with a greater
percentage of umbilical artery pH ≤ 7.20 when it is given to induce labor.
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